Trial Profile
A Randomized, Open-Label, Phase 2a Comparator Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L-Ornithine Phenylacetate) Versus Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic Encephalopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2021
Price :
$35
*
At a glance
- Drugs Ornithine phenylacetate (Primary) ; Rifaximin
- Indications Liver cirrhosis
- Focus Pharmacodynamics
- Sponsors Mallinckrodt Inc.
- 21 Jul 2020 Status changed from recruiting to completed.
- 06 May 2020 Planned End Date changed from 31 Mar 2020 to 31 Aug 2020.
- 06 May 2020 Planned primary completion date changed from 31 Mar 2020 to 31 Aug 2020.